BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018. Pharmacoeconomics 2020;38:1135-45. [PMID: 32696192 DOI: 10.1007/s40273-020-00942-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Vellekoop H, Versteegh M, Huygens S, Corro Ramos I, Szilberhorn L, Zelei T, Nagy B, Tsiachristas A, Koleva-kolarova R, Wordsworth S, Rutten-van Mölken M. The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis. Value in Health 2022. [DOI: 10.1016/j.jval.2022.01.006] [Reference Citation Analysis]
2 Yuen SC, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, Mattingly TJ 2nd. A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. Pharmacoecon Open 2021. [PMID: 34427897 DOI: 10.1007/s41669-021-00298-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Neumann PJ, Cohen JT, Kim DD, Ollendorf DA. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic: Study reviews alternative pricing strategies (cost-recovery models, monetary prizes, advanced market commitments) for COVID-19 drugs, vaccines, and diagnostics. Health Affairs 2021;40:53-61. [DOI: 10.1377/hlthaff.2020.01548] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
4 Laberge M, Coulibaly LP, Berthelot S, Borges da Silva R, Guertin JR, Strumpf E, Poirier A, Zomahoun HTV, Poder TG. Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire. Value Health 2021;24:1172-81. [PMID: 34372983 DOI: 10.1016/j.jval.2021.03.016] [Reference Citation Analysis]
5 Silver MC, Neumann PJ, Ma S, Kim DD, Cohen JT, Nyaku M, Roberts C, Sinha A, Ollendorf DA. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine 2021;39:6727-34. [PMID: 34656380 DOI: 10.1016/j.vaccine.2021.09.070] [Reference Citation Analysis]
6 Park JY, Marcum ZA, Garrison LP. Toward a broader concept of societal value: family spillovers in Alzheimer's disease. Int J Technol Assess Health Care 2022;38. [DOI: 10.1017/s0266462321000593] [Reference Citation Analysis]
7 Gudgeon JM, Varner MW, Hao J, Williams MS. Model-Based Re-Examination of the Effectiveness of Tumor/Immunohistochemistry and Direct-to-Sequencing Protocols for Lynch Syndrome Case Finding in Endometrial Cancer. JCO Oncol Pract 2021;:OP2000988. [PMID: 33886346 DOI: 10.1200/OP.20.00988] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rezapour A, Souresrafil A, Arabloo J. Economic Evaluation of New Oral Anticoagulants in Prevention of Venous Thrombosis Following Joint Replacement Surgery: A Systematic Review. Clin Ther 2021;43:e139-56. [PMID: 33875243 DOI: 10.1016/j.clinthera.2021.03.012] [Reference Citation Analysis]
9 Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia. Am J Hematol 2022. [PMID: 35147241 DOI: 10.1002/ajh.26497] [Reference Citation Analysis]
10 Dennen S, Díaz Espinosa O, Birch K, Cai J, Sung JC, Machado PGP, Shafrin J. Quantifying spillover benefits in value assessment: a case study of increased graft survival on the US kidney transplant waitlist. J Med Econ 2021;24:918-28. [PMID: 34275421 DOI: 10.1080/13696998.2021.1957287] [Reference Citation Analysis]
11 Mutyambizi-Mafunda V, Myers B, Sorsdahl K, Chanakira E, Lund C, Cleary S. Economic evaluations of psychological treatments for common mental disorders in low- and middle-income countries: protocol for a systematic review. Glob Health Action 2021;14:1972561. [PMID: 34514969 DOI: 10.1080/16549716.2021.1972561] [Reference Citation Analysis]
12 Heun-Johnson H, Zuluaga KV, Menchine M, Starkey S, David RF, Seabury S. Assessing the Use of Data Systems to Estimate Return-on-Investment of Behavioral Healthcare Interventions: Opportunities and Barriers. J Behav Health Serv Res 2022. [PMID: 35415803 DOI: 10.1007/s11414-022-09794-4] [Reference Citation Analysis]
13 Ma S, Olchanski N, Cohen JT, Ollendorf DA, Neumann PJ, Kim DD. The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value in Health 2022. [DOI: 10.1016/j.jval.2022.01.025] [Reference Citation Analysis]
14 Gold HT, Mcdermott C, Hoomans T, Wagner TH. Cost data in implementation science: categories and approaches to costing. Implementation Sci 2022;17. [DOI: 10.1186/s13012-021-01172-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
15 Byun JY, Park SK, Ng BP, Liu YS, Kim CR, Park C. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opin Pharmacother 2022;:1-11. [PMID: 35759783 DOI: 10.1080/14656566.2022.2095203] [Reference Citation Analysis]
16 Neumann PJ, Podolsky MI, Basu A, Ollendorf DA, Cohen JT. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications. Value Health 2022;25:59-68. [PMID: 35031100 DOI: 10.1016/j.jval.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vissapragada R, Bulamu N, Karnon J, Yazbek R, Watson DI. Cost-effectiveness in surgery: concepts of cost-utility analysis explained. ANZ J Surg 2021;91:1717-23. [PMID: 33480173 DOI: 10.1111/ans.16586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Portnoy A, Pedersen K, Nygård M, Trogstad L, Kim JJ, Burger EA. Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis. Med Decis Making 2022;:272989X221082683. [PMID: 35255741 DOI: 10.1177/0272989X221082683] [Reference Citation Analysis]
19 Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health 2022;25:10-31. [PMID: 35031088 DOI: 10.1016/j.jval.2021.10.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 20.0] [Reference Citation Analysis]
20 Loong D, Pham B, Amiri M, Saunders H, Mishra S, Radhakrishnan A, Rodrigues M, Yeung MW, Muller MP, Straus SE, Tricco AC, Isaranuwatchai W. Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value Health 2022:S1098-3015(22)00153-X. [PMID: 35659487 DOI: 10.1016/j.jval.2022.03.011] [Reference Citation Analysis]
21 Bertolaccini L, Ciani O, Spaggiari L. Comment on The Unbearable Lightness of Difference Between Statistical and Clinical Significance. Annals of Surgery Open 2022;3:e114. [DOI: 10.1097/as9.0000000000000122] [Reference Citation Analysis]
22 Jayasundera KT, Abuzaitoun RO, Lacy GD, Abalem MF, Saltzman GM, Ciulla TA, Johnson MW. Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases. Am J Ophthalmol 2022;235:90-7. [PMID: 34433085 DOI: 10.1016/j.ajo.2021.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 K S, Shankar R. Healthcare Cost Reduction and Health Insurance Policy Improvement. Value Health Reg Issues 2021;29:93-9. [PMID: 34902812 DOI: 10.1016/j.vhri.2021.10.001] [Reference Citation Analysis]
24 Neumann PJ, Ollendorf DA, Cohen JT. Value-based drug pricing in the Biden era: Opportunities and prospects. Health Serv Res 2021. [PMID: 34085289 DOI: 10.1111/1475-6773.13686] [Reference Citation Analysis]
25 Grosse SD, Zhou Y. Monetary Valuation of Children's Cognitive Outcomes in Economic Evaluations from a Societal Perspective: A Review. Children (Basel) 2021;8:352. [PMID: 33946651 DOI: 10.3390/children8050352] [Reference Citation Analysis]
26 Podolsky MI, Present I, Neumann PJ, Kim DD. A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-health Impacts and Distributional Issues. Value in Health 2022. [DOI: 10.1016/j.jval.2022.02.003] [Reference Citation Analysis]
27 Neumann PJ, Garrison LP, Willke RJ. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health 2022. [DOI: 10.1016/j.jval.2022.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 van Dover TJ, Kim DD. Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence? Value Health 2021;24:1586-91. [PMID: 34711358 DOI: 10.1016/j.jval.2021.03.017] [Reference Citation Analysis]
29 Chambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? Pharmacoeconomics 2021. [PMID: 34697718 DOI: 10.1007/s40273-021-01096-5] [Reference Citation Analysis]
30 Ito K, Chapman R, Pearson SD, Tafazzoli A, Yaffe K, Gurwitz JH. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors. JAMA Netw Open 2021;4:e2129392. [PMID: 34677596 DOI: 10.1001/jamanetworkopen.2021.29392] [Reference Citation Analysis]
31 Chukhray N, Mrykhina O, Izonin I. Holistic Approach to R&D Products’ Evaluation for Commercialization under Open Innovations. JOItmC 2022;8:9. [DOI: 10.3390/joitmc8010009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
32 Grosse SD, Gudgeon JM. Cost or price of sequencing? Implications for economic evaluations in genomic medicine. Genet Med 2021;23:1833-5. [PMID: 34113006 DOI: 10.1038/s41436-021-01223-9] [Reference Citation Analysis]
33 Ananthapavan J, Sacks G, Orellana L, Marshall J, Robinson E, Moodie M, Blake M, Brown A, Carter R, Cameron AJ. Cost-Benefit and Cost-Utility Analyses to Demonstrate the Potential Value-for-Money of Supermarket Shelf Tags Promoting Healthier Packaged Products in Australia. Nutrients 2022;14:1919. [PMID: 35565886 DOI: 10.3390/nu14091919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. Adv Ther 2021;38:1811-31. [PMID: 33650025 DOI: 10.1007/s12325-021-01654-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]